Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells

Journal of Pineal Research

Volumn 49, Issue 2, 2010, Pages 141-148

  Romero, Alejandro ^a,b   Egea, Javier ^a,b   García, Antonio G ^a,b,c   López, Manuela G ^a,b  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

galantamine; melatonin; neuroprotection; oxidative stress; synergic

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ACETYLCHOLINESTERASE; CHELERYTHRINE; GALANTAMINE; HEME OXYGENASE 1; LACTATE DEHYDROGENASE; LUZINDOLE; MECAMYLAMINE; MELATONIN; MELATONIN RECEPTOR; MITOCHONDRIAL COMPLEX V; NICOTINIC RECEPTOR; OLIGOMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; PROTOPORPHYRIN TIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANTIOXIDANT ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; NEUROBLASTOMA CELL; NEUROPROTECTION; OXIDATIVE STRESS;

EID: 77955169904     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2010.00778.x     Document Type: Article

References (52)

1. Chauhan V, Chauhan A. Oxidative stress in Alzheimer's disease. Pathophysiology 2006 13 : 195 208.
2. Klein JA, Ackerman SL. Oxidative stress, cell cycle, and neurodegeneration. J Clin Invest 2003 111 : 785 793.
3. Lipton SA, Gu Z, Nakamura T. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. Int Rev Neurobiol 2007 82 : 1 27.
4. Moreira PI, Siedlak SL, Aliev G et al. Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J Neural Transm 2005 112 : 921 932.
5. Dexter DT, Carter CJ, Wells FR et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989 52 : 381 389.
6. Hensley K, Maidt ML, Yu Z et al. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 1998 18 : 8126 8132.
7. Butterfield DA, Castegna A, Lauderback CM et al. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 2002 23 : 655 664.
8. Pedersen WA, Fu W, Keller JN et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol 1998 44 : 819 824.
9. Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 1990 46 : 1553 1558.
10. Geerts H. Indicators of neuroprotection with galantamine. Brain Res Bull 2005 64 : 519 524.
11. Coyle JT, Geerts H, Sorra K et al. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J Alzheimers Dis 2007 11 : 491 507.
12. Tan DX, Manchester LC, Reiter RJ et al. Melatonin directly scavenges hydrogen peroxide: a potentially new metabolic pathway of melatonin biotransformation. Free Radic Biol Med 2000 29 : 1177 1185.
13. Reiter RJ, Tan DX, Manchester LC et al. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 2001 34 : 237 256.
14. Peyrot F, Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res 2008 45 : 235 246.
15. Hardeland R, Tan DX, Reiter RJ. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009 47 : 109 126.
16. Reiter RJ, Paredes SD, Manchester LC et al. Reducing oxidative/ nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009 44 : 175 200.
17. Weishaupt JH, Bartels C, Polking E et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006 41 : 313 323.
18. Herrera J, Nava M, Romero F et al. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 2001 37 : 750 757.
19. Kedziora-Kornatowska K, Szewczyk-Golec K, Kozakiewicz M et al. Melatonin improves oxidative stress parameters measured in the blood of elderly type 2 diabetic patients. J Pineal Res 2009 46 : 333 337.
20. Hoglinger GU, Lannuzel A, Khondiker ME et al. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 2005 95 : 930 939.
21. Arias E, Gallego-Sandin S, Villarroya M et al. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther 2005 315 : 1346 1353.
22. Kim MS, Kim MK, Kim KS et al. Cytotoxicity of 1,2-diacetylbenzene in human neuroblastoma SHSY5Y cells is mediated by oxidative stress. Toxicology 2008 243 : 216 223.
23. Mcmillan CR, Sharma R, Ottenhof T et al. Modulation of tyrosine hydroxylase expression by melatonin in human SH-SY5Y neuroblastoma cells. Neurosci Lett 2007 419 : 202 206.
24. Lukas RJ, Norman SA, Lucero L. Characterization of nicotinic acetylcholine receptors expressed by cells of the SH-SY5Y human neuroblastoma clonal line. Mol Cell Neurosci 1993 4 : 1 12.
25. Peng X, Katz M, Gerzanich V et al. Human alpha 7 acetylcholine receptor: cloning of the alpha 7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional alpha 7 homomers expressed in xenopus oocytes. Mol Pharmacol 1994 45 : 546 554.
26. Bolognesi ML, Matera R, Minarini A et al. Alzheimer's disease: new approaches to drug discovery. Curr Opin Chem Biol 2009 13 : 303 308.
27. Cavalli A, Bolognesi ML, Capsoni S et al. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Ed Engl 2007 46 : 3689 3692.
28. Schmitt B, Bernhardt T, Moeller HJ et al. Combination therapy in Alzheimer's disease: a review of current evidence. CNS Drugs 2004 18 : 827 844.
29. Alva G, Cummings JL. Relative tolerability of Alzheimer's disease treatments. Psychiatry (Edgmont) 2008 5 : 27 36.
30. Reiter RJ, Tan DX, Sainz RM et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002 54 : 1299 1321.
31. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986 89 : 271 277.
32. Koh JY, Choi DW. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurosci Methods 1987 20 : 83 90.
33. Sobrado M, Roda JM, Lopez MG et al. Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. Neurosci Lett 2004 365 : 132 136.
34. Egea J, Rosa AO, Cuadrado A et al. Nicotinic receptor activation by epibatidine induces heme oxygenase-1 and protects chromaffin cells against oxidative stress. J Neurochem 2007 102 : 1842 1852.
35. Lorrio S, Negredo P, Roda JM et al. Effects of memantine and galantamine given separately or in association, on memory and hippocampal neuronal loss after transient global cerebral ischemia in gerbils. Brain Res 2009 1254 : 128 137.
36. Lorrio S, Sobrado M, Arias E et al. Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils. J Pharmacol Exp Ther 2007 322 : 591 599.
37. Arias E, Ales E, Gabilan NH et al. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004 46 : 103 114.
38. Kihara T, Sawada H, Nakamizo T et al. Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem Biophys Res Commun 2004 325 : 976 982.
39. Maelicke A, Samochocki M, Jostock R et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001 49 : 279 288.
40. Albuquerque EX, Santos MD, Alkondon M et al. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2001 15 (Suppl. 1 S19 S25.
41. Traykova M, Traykov T, Hadjimitova V et al. Antioxidant properties of galantamine hydrobromide. Z Naturforsch C 2003 58 : 361 365.
42. Osseni RA, Rat P, Bogdan A et al. Evidence of prooxidant and antioxidant action of melatonin on human liver cell line HepG2. Life Sci 2000 68 : 387 399.
43. Das A, Belagodu A, Reiter RJ et al. Cytoprotective effects of melatonin on C6 astroglial cells exposed to glutamate excitotoxicity and oxidative stress. J Pineal Res 2008 45 : 117 124.
44. Olcese JM, Cao C, Mori T et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res 2009 47 : 82 96.
45. Kihara T, Shimohama S, Sawada H et al. alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 2001 276 : 13541 13546.
46. Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 1998 56 : 359 384.
47. Vanecek J. Cellular mechanisms of melatonin action. Physiol Rev 1998 78 : 687 721.
48. Tuominen RK, Mcmillian MK, Ye H et al. Long-term activation of protein kinase C by nicotine in bovine adrenal chromaffin cells. J Neurochem 1992 58 : 1652 1658.
49. Bobrovskaya L, Gilligan C, Bolster EK et al. Sustained phosphorylation of tyrosine hydroxylase at serine 40: a novel mechanism for maintenance of catecholamine synthesis. J Neurochem 2007 100 : 479 489.
50. Rodriguez C, Mayo JC, Sainz RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004 36 : 1 9.
51. Kim YS, Zhuang H, Koehler RC et al. Distinct protective mechanisms of HO-1 and HO-2 against hydroperoxide-induced cytotoxicity. Free Radic Biol Med 2005 38 : 85 92.
52. Fernandez-Bachiller MI, Perez C, Campillo NE et al. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem 2009 4 : 828 841.